Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

BAVARIAN NORDIC

BAVA.CODK0015998017NASDAQ CopenhagenDKDKK
Stock price
BAVARIAN NORDIC
Loading chart...

Coverage

Latest articles

Bavarian Nordic board backs higher bid amid shareholder holdout
16 Oct 2025, 05:28BAVA.CONASDAQ Copenhagen

Bavarian Nordic's board of directors on Thursday reiterated its recommendation for shareholders to accept a takeover offer from a private equity consortium led by Nordic Capital and Permira.

Private equity raises Bavarian Nordic bid, faces shareholder test
15 Oct 2025, 15:59BAVA.CONASDAQ Copenhagen

A private equity consortium led by Nordic Capital and Permira has raised its takeover bid for Danish vaccine maker Bavarian Nordic to 250 Danish Krone per share from 233 Danish Krone.

Nordic Capital, Permira clear final hurdle for Bavarian Nordic takeover
9 Oct 2025, 12:24BAVA.CONASDAQ Copenhagen

A consortium led by private equity firms Nordic Capital and Permira has received the final regulatory approval needed for its proposed takeover of Danish vaccine maker Bavarian Nordic.

Bavarian Nordic's mpox vaccine shows strong results in children
7 Oct 2025, 14:59BAVA.CONASDAQ Copenhagen

Bavarian Nordic said Tuesday its mpox and smallpox vaccine produced a strong immune response and was well-tolerated in children aged 2 to 11 in a clinical study.

Bavarian Nordic posts strong results ahead of PE buyout
22 Aug 2025, 05:38BAVA.CONASDAQ Copenhagen

Danish vaccine maker Bavarian Nordic on Friday reported a 33% rise in first-half revenue, posting strong results as it prepares for a takeover by a private equity consortium.

Bavarian Nordic agrees to DKK 19 billion takeover offer
6 Aug 2025, 20:30BAVA.CONASDAQ Copenhagen

A consortium led by private equity firms Nordic Capital and Permira has agreed to acquire Danish vaccine maker Bavarian Nordic in an all-cash deal valuing the company at approximately 19 billion Danish Krone.

  • Previous
  • 1
  • 2

Filings

Recent filings

FilingDate
Bavarian Nordic receives USD 25 million milestone payment after submission of important IMVAMUNE® data to the U.S. Health Authorities19 Nov 2008
Bavarian Nordic reports successful safety data from Phase II study with IMVAMUNE®5 Nov 2008
Bavarian Nordic A/S - Interim Report for the period 1 January to 30 September 20084 Nov 2008
Bavarian Nordic awards warrants to management and certain employees and introduces incentive programme for all employees17 Oct 2008
Bavarian Nordic announces positive mature Phase II results from newly acquired prostate cancer vaccine7 Oct 2008
Bavarian Nordic A/S - Interim Report for the period 1 January to 30 June 200819 Aug 2008
Bavarian Nordic announces partnership with National Cancer Institute in the US and obtains rights to a new vaccine candidate13 Aug 2008
Bavarian Nordic files patent infringement suit against Oxford BioMedica30 Jun 2008
Bavarian Nordic reports interim data from Phase I/II studies with breast cancer vaccine19 Jun 2008
Bavarian Nordic enters clinical trials with prostate cancer vaccine3 Jun 2008
Bavarian Nordic enters clinical trials with HIV multiantigen vaccine27 May 2008
Bavarian Nordic A/S - Report on the Results of the Extraordinary General Meeting, held 26 May 200826 May 2008
  • Previous
  • 1
  • More pages
  • 58
Search
Company
BAVARIAN NORDIC
BAVA.CONASDAQ Copenhagen
Website: Unavailable
Coverage
14
  • 3
  • Next
  • 59
  • 60
  • More pages
  • 78
  • Next
  • Filings
    927